Tobias Egle has left his role working for the tech and biotech venture fund M Ventures after three years at the CVC.
Tobias Egle, photo courtesy of LinkedIn
Tobias Egle has left his role as an investment associate at M Ventures, the CVC arm of the German science and technology company Merck.
Egle joined in February 2022. Before that, he was a fellow at Yard Ventures, a VC firm that raises money from Harvard University alumni to invest in startups run by alumni but which is not affiliated with the university. As a fellow, he worked on due diligence and deal sourcing.
During his time with M Ventures, Egle sat as a board observer on some of the fund’s portfolio companies, including Polaris Electro-Optics, which makes photonics technology for data transfer, and Quintessent, which works on communication between chips through optical connectivity technology.
He was also a member of the board of NovoLinc, another portfolio company. It makes thermal interfaces for semiconductors to help keep them cool.
M Ventures was launched in 2019. It invests in healthcare and life science startups, as well as deep tech startups in areas such as clean tech and semiconductors.
